I期临床试验-话题@MedSci

#I期临床试验#

226篇内容 | 3902人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2088802, encodeId=63e320888027d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始, objectType=article, longId=193525, objectId=9a4819352542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a4819352542, replyNumber=0, likeNumber=59, createdTime=2020-12-31, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a4819352542, moduleTitle=AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a4819352542)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088787, encodeId=298c2088e87b3, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验, objectType=article, longId=189176, objectId=3c381891e64b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c381891e64b, replyNumber=0, likeNumber=56, createdTime=2020-03-22, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c381891e64b, moduleTitle=J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c381891e64b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088785, encodeId=a4772088e85fd, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果, objectType=article, longId=187677, objectId=e89218e67760, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e89218e67760, replyNumber=0, likeNumber=59, createdTime=2020-07-01, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e89218e67760, moduleTitle=芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e89218e67760)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088807, encodeId=46a2208880e4f, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=免疫应答率100%！陈薇院士团队柳叶刀报告全球新冠疫苗I期临床试验结果, objectType=article, longId=194887, objectId=4dff19488e70, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dff19488e70, replyNumber=0, likeNumber=98, createdTime=2021-02-22, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dff19488e70, moduleTitle=免疫应答率100%！陈薇院士团队柳叶刀报告全球新冠疫苗I期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dff19488e70)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088777, encodeId=913a2088e77ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, objectType=article, longId=185522, objectId=448618552283, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=448618552283, replyNumber=0, likeNumber=59, createdTime=2020-08-14, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=448618552283, moduleTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=448618552283)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088753, encodeId=eeb72088e5374, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, objectType=article, longId=174364, objectId=c1da1e436402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1da1e436402, replyNumber=0, likeNumber=110, createdTime=2020-01-24, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1da1e436402, moduleTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1da1e436402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088797, encodeId=9e5e2088e97c7, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=患者招募：评价SCB-313用于治疗腹膜癌患者的I期临床试验, objectType=article, longId=192309, objectId=fb70192309d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb70192309d8, replyNumber=0, likeNumber=72, createdTime=2021-01-27, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb70192309d8, moduleTitle=患者招募：评价SCB-313用于治疗腹膜癌患者的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb70192309d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088774, encodeId=b52b2088e74b4, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验, objectType=article, longId=185186, objectId=397c185186ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397c185186ea, replyNumber=0, likeNumber=71, createdTime=2020-08-08, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397c185186ea, moduleTitle=儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397c185186ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088795, encodeId=bc1b2088e951c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准, objectType=article, longId=191868, objectId=b01e191868d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b01e191868d2, replyNumber=0, likeNumber=60, createdTime=2020-10-22, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b01e191868d2, moduleTitle=OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b01e191868d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088764, encodeId=3f152088e6434, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Onngsertib治疗转移性去势抵抗性前列腺癌的II期临床试验取得成功, objectType=article, longId=178245, objectId=e1fa1e8245bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1fa1e8245bc, replyNumber=0, likeNumber=74, createdTime=2020-05-24, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1fa1e8245bc, moduleTitle=Onngsertib治疗转移性去势抵抗性前列腺癌的II期临床试验取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1fa1e8245bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088756, encodeId=37702088e56ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Sanfilippo综合征A型的基因疗法：基因疗法ABO-102的I/II期临床试验取得阶段性成果, objectType=article, longId=176224, objectId=18291e622416, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18291e622416, replyNumber=0, likeNumber=68, createdTime=2020-03-24, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18291e622416, moduleTitle=Sanfilippo综合征A型的基因疗法：基因疗法ABO-102的I/II期临床试验取得阶段性成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18291e622416)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088755, encodeId=33c02088e5566, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=2019年国际血栓和止血学会：II期临床试验抗组织因子抑制剂单抗Concizumab对A/B型血友病患者安全有效, objectType=article, longId=175613, objectId=674d1e56136b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=674d1e56136b, replyNumber=0, likeNumber=85, createdTime=2020-05-22, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=674d1e56136b, moduleTitle=2019年国际血栓和止血学会：II期临床试验抗组织因子抑制剂单抗Concizumab对A/B型血友病患者安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=674d1e56136b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088751, encodeId=9e142088e51bb, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Lancet：IPH4102治疗晚期T细胞淋巴瘤的I期临床试验结果, objectType=article, longId=174329, objectId=68c11e432912, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68c11e432912, replyNumber=0, likeNumber=58, createdTime=2019-12-13, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68c11e432912, moduleTitle=Lancet：IPH4102治疗晚期T细胞淋巴瘤的I期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68c11e432912)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088748, encodeId=28362088e48d5, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=第24届EHA大会：5F9联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤的Ib / II期临床试验, objectType=article, longId=168728, objectId=5792168e289d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5792168e289d, replyNumber=0, likeNumber=80, createdTime=2020-04-11, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5792168e289d, moduleTitle=第24届EHA大会：5F9联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤的Ib / II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5792168e289d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088772, encodeId=642e2088e7209, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果, objectType=article, longId=184569, objectId=5a93184569d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a93184569d3, replyNumber=0, likeNumber=78, createdTime=2020-07-17, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a93184569d3, moduleTitle=复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a93184569d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088750, encodeId=2c0a2088e501d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=短肠综合征：双效多肽药物ZP7570正在进行I期临床试验, objectType=article, longId=174327, objectId=f0d81e432731, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0d81e432731, replyNumber=0, likeNumber=66, createdTime=2020-01-08, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0d81e432731, moduleTitle=短肠综合征：双效多肽药物ZP7570正在进行I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0d81e432731)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088768, encodeId=c5c72088e683b, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Cymerus MSCs治疗骨关节炎的II期临床试验取得新进展, objectType=article, longId=180575, objectId=9db31805e5fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9db31805e5fb, replyNumber=0, likeNumber=148, createdTime=2020-07-12, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9db31805e5fb, moduleTitle=Cymerus MSCs治疗骨关节炎的II期临床试验取得新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9db31805e5fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088776, encodeId=a8a72088e76f1, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=HB-201治疗人乳头瘤病毒16阳性癌症的I/II期临床试验, objectType=article, longId=185521, objectId=11cc18552145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11cc18552145, replyNumber=0, likeNumber=50, createdTime=2020-07-16, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11cc18552145, moduleTitle=HB-201治疗人乳头瘤病毒16阳性癌症的I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11cc18552145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088792, encodeId=4c9b2088e9285, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验, objectType=article, longId=190723, objectId=c191190e23e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c191190e23e2, replyNumber=0, likeNumber=66, createdTime=2020-05-21, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c191190e23e2, moduleTitle=FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c191190e23e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088767, encodeId=33eb2088e6785, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=面肩肱型肌营养不良症（FSHD）：Losmapimod的I期临床试验取得积极结果, objectType=article, longId=180555, objectId=cca71805552c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cca71805552c, replyNumber=0, likeNumber=85, createdTime=2019-12-18, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cca71805552c, moduleTitle=面肩肱型肌营养不良症（FSHD）：Losmapimod的I期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cca71805552c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床试验

2020-05-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始

2020-12-31

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验

2020-03-22

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果

2020-07-01

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

免疫应答率100%！陈薇院士团队柳叶刀报告全球新冠疫苗I期临床试验结果

2021-02-22

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始

2020-08-14

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点

2020-01-24

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

患者招募：评价SCB-313用于治疗腹膜癌患者的I期临床试验

2021-01-27

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验

2020-08-08

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准

2020-10-22

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Onngsertib治疗转移性去势抵抗性前列腺癌的II期临床试验取得成功

2020-05-24

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Sanfilippo综合征A型的基因疗法：基因疗法ABO-102的I/II期临床试验取得阶段性成果

2020-03-24

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

2019年国际血栓和止血学会：II期临床试验抗组织因子抑制剂单抗Concizumab对A/B型血友病患者安全有效

2020-05-22

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Lancet：IPH4102治疗晚期T细胞淋巴瘤的I期临床试验结果

2019-12-13

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

第24届EHA大会：5F9联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤的Ib / II期临床试验

2020-04-11

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果

2020-07-17

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

短肠综合征：双效多肽药物ZP7570正在进行I期临床试验

2020-01-08

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Cymerus MSCs治疗骨关节炎的II期临床试验取得新进展

2020-07-12

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

HB-201治疗人乳头瘤病毒16阳性癌症的I/II期临床试验

2020-07-16

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验

2020-05-21

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

面肩肱型肌营养不良症（FSHD）：Losmapimod的I期临床试验取得积极结果

2019-12-18

科室
- - 订阅+
  - 更多科室
工具
服务